This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Protein Replacement through Nucleic Acid Therapies
Organizer(s): Pad Chivukula, Jean Bennett and Paloma Giangrande
Date: April 07 - 10, 2019
Location: Steamboat Grand, Steamboat Springs, CO, USA
Sponsored by Moderna, Novo Nordisk A/S and Sarepta Therapeutics
Summary of Meeting:
Protein replacement therapy based on recombinant protein has so far been limited to genetic diseases in which the mutated protein acts extracellularly. Nucleic acid therapies such as gene therapy and messenger RNA enable replacement of intracellular proteins, or extracellular proteins too complex to manufacture. This opens up the potential to treat many previously unapproachable diseases. After early setbacks in gene therapy, a new generation of therapeutics are showing progress in the clinic. Novel messenger RNA and RNA delivery technologies are also in development, the potential of which is only beginning to be demonstrated. These represent exciting areas of therapeutic development which also touch on fundamental questions about regulation of gene expression, protein production, and immunity. This conference brings these communities together to discuss common challenges and complementarities, providing an opportunity for cross-fertilization.
Scholarship Deadline: January 8 2019
Discounted Abstract Deadline: January 8 2019
Abstract Deadline: February 5 2019
Discounted Registration Deadline: February 5 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
ModernaNovo Nordisk A/SSarepta Therapeutics
We gratefully acknowledge additional support from these exhibitors at this conference:
TriLink BioTechnologies, Inc.
We gratefully acknowledge additional support for this conference from:
American Society of Gene & Cell Therapy (ASGCT)Arcturus Therapeutics, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Arcturus Therapeutics, Inc.

Burke Bioventures

Moderna

Spark Therapeutics

Translate Bio
We gratefully acknowledge the generous grant for this conference provided by:

National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR002781-01
Funding for this conference was made possible (in part) by 1R13TR002781-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found